

## SHAREHOLDERS' MEETING 2026 - DIASORIN S.P.A.

THE ORDINARY SHAREHOLDERS' MEETING OF DIASORIN S.P.A. HELD TODAY:

- APPROVED THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2025 AND THE DISTRIBUTION OF A DIVIDEND OF € 1.30 PER SHARE
- APPROVED THE REMUNERATION POLICY AND THE "SECOND SECTION" OF THE REPORT ON THE REMUNERATION POLICY AND COMPENSATION PAID PURSUANT TO ART. 123-TER OF LEGISLATIVE DECREE 58/1998
- APPROVED PURSUANT TO ART. 114-BIS OF LEGISLATIVE DECREE NO. 58/1998 THE ESTABLISHMENT OF A NEW STOCK OPTION PLAN

**April 29, 2026** - Diasorin S.p.A. (FTSE MIB: DIA) announces that the Ordinary Shareholders' Meeting, held today under the chairmanship of Mr. Michele Denegri, with a shareholding in attendance equal to 83.65% of the voting rights, took note of the consolidated results achieved by the Group and approved the Financial Statements for the year ended December 31, 2025.

The Shareholders' Meeting also approved the distribution of a dividend of € 1.30 for each share entitled, gross of withholding taxes, with ex date on 18 May 2026, record date on 19 May 2026, payment date on 20 May 2026, for a total of € 65,303,109<sup>1</sup>.

The same Shareholders' Meeting, in compliance with Article 123-ter of Legislative Decree 58/1998, approved with a binding resolution the Company's policy on the remuneration of members of the administrative and control bodies, general managers and executives with strategic responsibilities as well as, with a non-binding resolution, the "Second Section" of the Report on the Remuneration Policy and the remuneration paid in the financial year 2025.

Today's Shareholders' Meeting also approved, pursuant to Article 114 bis of Legislative Decree 58/1998, the establishment of a new stock option plan called "Stock Option Plan 2026 - DIASORIN S.p.A." reserved for executives and employees of Diasorin and its direct or indirect subsidiaries ("2026 Plan"). The characteristics of the 2026 Plan (including the conditions and assumptions for implementation) are described in the respective Explanatory Report of the Board of Directors and in the respective information document prepared pursuant to Article 84-bis of the Issuers' Regulation no. 11971/1999, which can be consulted, among other things, on the Company's website. The 2026 Plan will have a three-year duration and provides for a maximum number of 600,000 options (valid for the purchase of treasury ordinary shares in the Company's portfolio in a 1:1 ratio) to be assigned free of charge to beneficiaries.

\* \* \*

For further information on the aforementioned Shareholders' Meeting resolutions, please refer to the explanatory reports presented by the Board of Directors, which can be consulted on the Company's website [int.diasorin.com](http://int.diasorin.com), section "Group"/"Governance"/"Shareholders' Meeting"/"2026").

In accordance with the law, the summary report of the votes will also be made available on the

---

<sup>1</sup> The total dividend of € 65,303,109 takes into account the no. 5,715,096 treasury shares held by Diasorin as of today. In consideration of the purchases that are planned and that may be carried out in execution of the *buyback program* authorized by the shareholders' meeting of January 27, 2026 and the treasury shares that will be canceled by virtue of the shareholders' resolution adopted in extraordinary session on the same date, the total amount of the dividend and, consequently, the amount to be allocated to reserves, will be determined according to the number of shares outstanding at the time of the ex-dividend date and the number of treasury shares actually held by the Company at the *record date*.

Company's website ("Company"/"Governance"/"Shareholders' Meeting"/"2026"). The minutes of the Shareholders' Meeting will be made available to the public in the manner and within the time limits provided for by current legislation.

**About Diasorin**

Headquartered in Italy and listed at the Italian Stock Exchange in the FTSE MIB Index, DiaSorin is a global leader in the In Vitro Diagnostic (IVD) field and is active since 2021 in the Life Science business. For over 50 years, the Company has been developing, producing and marketing reagent kits used by diagnostic laboratories worldwide.

The Group operates in 5 continents through 30 companies, 4 branches, 10 manufacturing facilities and 9 research and development centers. The extensive diagnostic testing and Life Science offer, made available through continuous investments in research, positions DiaSorin as the player with the broadest range of specialty tests available within the diagnostic market, and identifies the Group as the "Diagnostic Specialist".

More info at [www.diasorin.com](http://www.diasorin.com)

**FOR ADDITIONAL INFORMATION, PLEASE CONTACT:**

**INVESTOR RELATIONS**

**Riccardo Fava**

Corporate VP Communication, ESG & Investor Relations  
[riccardo.fava@diasorin.com](mailto:riccardo.fava@diasorin.com)

**Eugenia Ragazzo**

Corporate Investor Relations & ESG Senior Analyst  
[eugenia.ragazzo@diasorin.com](mailto:eugenia.ragazzo@diasorin.com)